The price of DICE Therapeutics Inc. (NASDAQ:DICE) shares last traded on Wall Street fell -9.41% to $28.51.
DICE stock price is now -6.69% away from the 50-day moving average and 14.47% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
, while ‘Guggenheim’ rates the stock as ‘Buy’.
In other news, RA CAPITAL MANAGEMENT, L.P., Director bought 1,640,000 shares of the company’s stock on Oct 17. The stock was bought for $59,860,000 at an average price of $36.50. Upon completion of the transaction, the Director now directly owns 6,848,911 shares in the company, valued at $195.26 million. A total of 3.39% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DICE stock. A new stake in DICE Therapeutics Inc. shares was purchased by ALKEON CAPITAL MANAGEMENT LLC during the first quarter worth $29,597,000. BRAIDWELL LP invested $23,922,000 in shares of DICE during the first quarter. In the first quarter, D. E. SHAW & CO., INC. acquired a new stake in DICE Therapeutics Inc. valued at approximately $19,470,000. NOVO HOLDINGS A/S acquired a new stake in DICE for approximately $13,257,000. FRANKLIN RESOURCES INC purchased a new stake in DICE valued at around $9,590,000 in the second quarter. In total, there are 151 active investors with 79.20% ownership of the company’s stock.
A candlestick chart of DICE Therapeutics Inc. (NASDAQ: DICE) showed a price of $31.00 on Tuesday morning. During the past 12 months, DICE Therapeutics Inc. has had a low of $12.64 and a high of $45.99. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 23.00, and a quick ratio of 23.00. The fifty day moving average price for DICE is $30.55 and a two-hundred day moving average price translates $24.91 for the stock.
The latest earnings results from DICE Therapeutics Inc. (NASDAQ: DICE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.55, beating analysts’ expectations of -$0.6 by 0.05. This compares to -$2.30 EPS in the same period last year. The company reported revenue of $21.17 million for the quarter, compared to $16.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 31.22 percent.
DICE Therapeutics Inc.(DICE) Company Profile
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
